Recent therapeutic advances in multisystem atrophy include treatments such as quinazolones, coenzyme Q10, mesenchymal stem cells, and myeloperoxidase inhibitors, but they are not yet in widespread clinical use. Currently it is possible to treat the symptoms.
Quinazolones can inhibit α-synuclein aggregation, and coenzyme Q10 can protect mitochondrial function, both of which are in clinical phase 2 trials; mesenchymal stem cells can protect and nourish nerves and slow disease progression; and myeloperoxidase inhibitors have entered clinical phase 3 trials with some effect.
These are currently newer treatments, but there is no large-scale clinical application to clarify the effect after large-scale clinical treatment.
For the treatment of multiple system atrophy, there are no targeted drugs and no specific drugs, only symptomatic drugs to relieve the symptoms.
1. Postural hypotension: you should rest more, try to hydrate more, you can wear compression stockings or abdominal use of pressure bands and other physical methods of treatment, the serious use of midodrine, drospirenine and other drugs.
2. Abnormal urination: such as urinary frequency, urinary urgency, etc., can use antispasmodic drugs, such as atropine, scopolamine. Mild urinary retention can be intermittent self-cleaning catheterization, and severe cases can be treated with injection of botulinum toxin type A or tamsulosin.
3. Parkinson’s syndrome: levodopa and amantadine can be used. Dystonia can be treated with botulinum toxin injection.
If the diagnosis of multiple system atrophy is confirmed, it should be actively treated under the guidance of a doctor to alleviate the symptoms. Drugs should all be used under the guidance of a doctor.